|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||5.01 / 10.25|
Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity
Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018
Company to pursue up-listing to a major stock exchange in 2017
2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal
SWK to Acquire Certain NARCAN® Royalties For Up to $17.5 Million
Thomas Brings Global Pharmaceutical and Financial Expertise to Opiant's Board
Listing Offers Product Exclusivity Until 2035
Approval Granted as Canada Confronts Opioid Crisis
Board Appointments Reflect Opiant's Development as a Commercial-Stage Pharmaceutical Company
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of OPNET Technologies Inc.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of OPNET Technologies, Inc.